Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMWV3TZ)

• Drug Name: Finasteride Drug Info
• Synonyms: Andozac; Eucoprost; FIT; Finasterida; Finasteridum; Finastid; Finpecia; Propecia; Propeshia; Proscar; Prostide; Cahill May Roberts Brand of Finasteride; Chibro Proscar; Frosst Iberica Brand of Finasteride; Lipha Brand of Finasteride; MSD Brand of Finasteride; MSD Chibropharm Brand of Finasteride; MK 0906; MK 906; MK906; Merck Brand 1 of Finasteride; Merck Brand 2 of Finasteride; Merck Frosst Brand 1 of Finasteride; Merck Frosst Brand 2 of Finasteride; Alternova (TN); Appecia (TN); Chibro-Proscar; Finalo (TN); Finara (TN); Finast (TN); Finasterid (TN); Finasterid IVAX (TN); Finasterida [INN-Spanish]; Finasteridum [INN-Latin]; Finax (TN); Fincar (TN); Finpecia (TN); Gefina (TN); KS-1058; MK-0906; MK-906; Merck Sharp & Dhome Brand 2 of Finasteride; Merck Sharp & Dohme Brand 1 of Finasteride; Propecia (TN); Proscar (TN); Prosteride (TN); YM-152; Finasteride (USP/INN); Finasteride [USAN:INN:BAN]; L-652,931; Proscar, Propecia, Finasteride; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; 17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one
• Therapeutic Class: Antihyperplasia Agents
• Cross-matching ID:
  PubChem CID: 57363
  ChEBI ID: CHEMBL710
  CAS Number: CAS 98319-26-7
  TTD Drug ID: D08IWD
  INTEDE Drug ID: DR0695
  ACDINA Drug ID: D00275

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	2.21	0.00e+0	34/36 (94.44%)	MCM3;MCM7;MCM5;...
Spliceosome	1.86	1.76e-2	101/150 (67.33%)	PRPF8;HNRNPA1;SNRPE;...
Ascorbate and aldarate metabolism	1.85	1.18e-2	15/30 (50%)	ALDH2;ALDH3A2;UGT2B17;...
Base excision repair	1.84	8.82e-3	29/33 (87.88%)	FEN1;APEX1;SMUG1;...
Ribosome biogenesis in eukaryotes	1.83	8.47e-3	52/108 (48.15%)	NVL;FBL;GTPBP4;...
Lysine degradation	1.82	8.24e-3	51/63 (80.95%)	SETDB1;ALDH2;ALDH3A2;...
Fatty acid degradation	1.79	1.31e-2	40/43 (93.02%)	ALDH2;ALDH3A2;ACADVL;...
Valine, leucine and isoleucine degradation	1.77	1.59e-2	42/48 (87.5%)	ACAD8;AUH;IVD;...
Pantothenate and CoA biosynthesis	1.73	2.51e-2	14/21 (66.67%)	ALDH2;ALDH3A2;BCAT2;...
Cell cycle	1.66	4.80e-2	110/124 (88.71%)	MCM3;MCM7;PRKDC;...
T cell receptor signaling pathway	-1.61	4.60e-2	93/104 (89.42%)	GSK3B;NCK2;MAPK14;...
Chemokine signaling pathway	-1.62	4.27e-2	163/192 (84.9%)	FOXO3;WAS;CCR10;...
Osteoclast differentiation	-1.63	4.29e-2	117/127 (92.13%)	TAB2;TNFRSF11A;FOSL1;...
PD-L1 expression and PD-1 checkpoint pathway in cancer	-1.64	4.07e-2	79/89 (88.76%)	STAT1;MAP2K3;MAPK14;...
Non-alcoholic fatty liver disease	-1.66	3.39e-2	126/155 (81.29%)	MAPK14;MAPK11;COX7C;...
Pertussis	-1.67	2.91e-2	64/76 (84.21%)	MAPK14;MAPK11;C1R;...
Thiamine metabolism	-1.68	2.66e-2	12/15 (80%)	ACP1;AK5;TPK1;...
RIG-I-like receptor signaling pathway	-1.70	2.39e-2	64/70 (91.43%)	MAPK14;MAPK11;NFKB1;...
Cytokine-cytokine receptor interaction	-1.70	2.32e-2	246/295 (83.39%)	CXCR6;IL21R;TNFRSF10D;...
African trypanosomiasis	-1.71	2.25e-2	32/37 (86.49%)	PRKCB;IL1B;IL18;...
Fluid shear stress and atherosclerosis	-1.73	1.85e-2	123/139 (88.49%)	MAPK14;MAPK11;MEF2A;...
Kaposi sarcoma-associated herpesvirus infection	-1.74	1.55e-2	172/193 (89.12%)	TCF7;EIF2AK2;STAT1;...
Prion disease	-1.75	1.42e-2	209/273 (76.56%)	MAPK14;MAPK11;COX7C;...
Parkinson disease	-1.76	1.43e-2	176/249 (70.68%)	COX7C;ATP5PF;UCHL1;...
Pathogenic Escherichia coli infection	-1.77	1.20e-2	152/197 (77.16%)	ARPC2;NCK2;TAB2;...
Vibrio cholerae infection	-1.81	8.52e-3	44/50 (88%)	ATP6V1E1;ATP6V0A2;ATP6V1F;...
Legionellosis	-1.85	7.30e-3	51/57 (89.47%)	IL1B;IL18;NFKBIA;...
Lysosome	-1.86	5.90e-3	115/128 (89.84%)	AP3S2;CTSD;SCARB2;...
Malaria	-1.86	6.39e-3	44/50 (88%)	THBS1;ACKR1;CD36;...
Lipid and atherosclerosis	-1.88	5.81e-3	190/215 (88.37%)	GSK3B;APOB;ATF6;...
Steroid biosynthesis	-1.90	5.11e-3	19/20 (95%)	LSS;CYP2R1;HSD17B7;...
Mineral absorption	-1.93	4.26e-3	48/60 (80%)	HMOX2;MT1X;ATOX1;...
Oxidative phosphorylation	-1.95	3.19e-3	93/133 (69.92%)	ATP6V1E1;ATP6V0A2;ATP6V1F;...
NOD-like receptor signaling pathway	-1.96	3.65e-3	145/181 (80.11%)	TAB2;HSP90AB1;STAT1;...
Viral protein interaction with cytokine and cytokine re...	-2.04	0.00e+0	84/100 (84%)	IL2RG;CCR10;CCL24;...
Rheumatoid arthritis	-2.04	0.00e+0	78/93 (83.87%)	ATP6V1E1;ATP6V0A2;TEK;...
NF-kappa B signaling pathway	-2.05	0.00e+0	90/104 (86.54%)	TAB2;TNFRSF11A;TNFSF14;...
TNF signaling pathway	-2.14	0.00e+0	103/112 (91.96%)	TAB2;MAP2K3;MAPK14;...
Epithelial cell signaling in Helicobacter pylori infect...	-2.22	0.00e+0	62/70 (88.57%)	ATP6V1E1;ATP6V0A2;ATP6V1F;...
IL-17 signaling pathway	-2.33	0.00e+0	84/94 (89.36%)	ELAVL1;GSK3B;TAB2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	6.66uM - 10uM	6H	Hide ▲

Bone marrow

Neuroblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
SH-SY5Y	CVCL_0019	Homo sapiens	0.04uM - 10uM	24H	Hide ▲
SK-N-SH	CVCL_0531	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	8uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 10uM	24H	Show ▼